diuretics | The Medical Letter Inc.

Matching articles for "diuretics"

In Brief: A New Torsemide Formulation (Soaanz) for Edema (online only)

The Medical Letter on Drugs and Therapeutics • August 19, 2024; (Issue 1709)

The FDA has approved Soaanz (Sarfez), a new formulation of the loop diuretic torsemide, for treatment of edema associated with heart failure or renal disease in adults. Torsemide has been...

The FDA has approved Soaanz (Sarfez), a new formulation of the loop diuretic torsemide, for treatment of edema associated with heart failure or renal disease in adults. Torsemide has been available generically for years for treatment of hypertension and treatment of edema due to heart failure, renal disease, or hepatic disease. According to the manufacturer, Soaanz tablets are formulated to provide a gradual and sustained diuresis, lowering the risk of excessive urination and hypokalemia.

Med Lett Drugs Ther. 2024 Aug 19;66(1709):e141 | Show Full Introduction Hide Full Introduction

Aprocitentan (Tryvio) for Hypertension

The Medical Letter on Drugs and Therapeutics • June 10, 2024; (Issue 1704)

The FDA has approved the dual endothelin receptor antagonist aprocitentan (Tryvio – Idorsia) for use in combination with other antihypertensive drugs to treat hypertension in adults whose blood pressure...

The FDA has approved the dual endothelin receptor antagonist aprocitentan (Tryvio – Idorsia) for use in combination with other antihypertensive drugs to treat hypertension in adults whose blood pressure is not adequately controlled on other drugs. Three other dual endothelin receptor antagonists, ambrisentan (Volibris, and generics), bosentan (Tracleer, and generics), and macitentan (Opsumit), are available in the US for treatment of pulmonary arterial hypertension.

Med Lett Drugs Ther. 2024 Jun 10;66(1704):92-3 | Show Full Introduction Hide Full Introduction

Drugs for Hypertension

The Medical Letter on Drugs and Therapeutics • May 27, 2024; (Issue 1703)

American College of Cardiology/American Heart Association (ACC/AHA) guidelines for treatment of hypertension were last published in 2018. Treatment of hypertensive urgencies and emergencies is not discussed...

Med Lett Drugs Ther. 2024 May 27;66(1703):81-8 | Show Full Introduction Hide Full Introduction

In Brief: Furoscix - A Subcutaneous Furosemide Infusor for Heart Failure

The Medical Letter on Drugs and Therapeutics • January 23, 2023; (Issue 1668)

The FDA has approved Furoscix (scPharmaceuticals), a subcutaneous formulation of the loop diuretic furosemide administered via a single-use, on-body infusor, for treatment of congestion due to...

The FDA has approved Furoscix (scPharmaceuticals), a subcutaneous formulation of the loop diuretic furosemide administered via a single-use, on-body infusor, for treatment of congestion due to fluid overload in adults with New York Heart Association (NYHA) Class II-III chronic heart failure (HF). Furosemide (Lasix, and generics) has been available for years in oral and IV formulations.

Med Lett Drugs Ther. 2023 Jan 23;65(1668):14-5 | Show Full Introduction Hide Full Introduction

Drugs for Chronic Heart Failure

The Medical Letter on Drugs and Therapeutics • June 14, 2021; (Issue 1626)

Among patients with chronic heart failure, those with a left ventricular ejection fraction (LVEF) ≤40% are considered to have heart failure with reduced ejection fraction (HFrEF). Patients with a LVEF ≥50% are considered to have heart failure with preserved ejection fraction (HFpEF). Those with a LVEF of 41-49% are an intermediate group more similar to patients with HFpEF.

Med Lett Drugs Ther. 2021 Jun 14;63(1626):89-96 | Show Full Introduction Hide Full Introduction

Vericiguat (Verquvo) for Heart Failure

The Medical Letter on Drugs and Therapeutics • March 8, 2021; (Issue 1619)

The FDA has approved vericiguat (Verquvo – Merck), an oral soluble guanylate cyclase (sGC) stimulator, to reduce the risk of hospitalization for heart failure and cardiovascular (CV) death following a...

The FDA has approved vericiguat (Verquvo – Merck), an oral soluble guanylate cyclase (sGC) stimulator, to reduce the risk of hospitalization for heart failure and cardiovascular (CV) death following a worsening heart failure event (hospitalization for heart failure or treatment with IV diuretics as an outpatient) in patients with symptomatic chronic heart failure and left ventricular ejection fraction (LVEF) <45%. Vericiguat is the second sGC stimulator to be marketed in the US. Riociguat (Adempas), which is FDA-approved for treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension, was the first.

Med Lett Drugs Ther. 2021 Mar 8;63(1619):36-7 | Show Full Introduction Hide Full Introduction

Comparison Table: Some Drugs for HFrEF (online only)

The Medical Letter on Drugs and Therapeutics • March 8, 2021; (Issue 1619)

...

View the Comparison Table: Some Drugs for HFrEF

Med Lett Drugs Ther. 2021 Mar 8;63(1619):e1-14 | Show Full Introduction Hide Full Introduction

In Brief: Hydrochlorothiazide and Skin Cancer

The Medical Letter on Drugs and Therapeutics • November 16, 2020; (Issue 1611)

The FDA has required the addition of information about an increased risk of nonmelanoma skin cancer (basal cell carcinoma [BCC] and squamous cell carcinoma [SCC]) to the labels of products containing the...

Med Lett Drugs Ther. 2020 Nov 16;62(1611):177 | Show Full Introduction Hide Full Introduction

Drugs for Hypertension

The Medical Letter on Drugs and Therapeutics • May 18, 2020; (Issue 1598)

Drugs available for treatment of chronic hypertension and their dosages, adverse effects, and costs are listed in the tables. Treatment of hypertensive urgencies and emergencies is not discussed...

Drugs available for treatment of chronic hypertension and their dosages, adverse effects, and costs are listed in the tables. Treatment of hypertensive urgencies and emergencies is not discussed here.

Med Lett Drugs Ther. 2020 May 18;62(1598):73-80 | Show Full Introduction Hide Full Introduction

Drugs for Chronic Heart Failure

The Medical Letter on Drugs and Therapeutics • April 8, 2019; (Issue 1569)

Patients with a left ventricular ejection fraction (LVEF) ≤40% are considered to have heart failure with reduced ejection fraction (HFrEF). Patients with a LVEF ≤50% and symptoms of heart failure are considered to have heart failure with preserved ejection fraction (HFpEF). There is little evidence that drug treatment improves clinical outcomes in patients with HFpEF.

Med Lett Drugs Ther. 2019 Apr 8;61(1569):49-54 | Show Full Introduction Hide Full Introduction

Expanded Table: Some Drugs for HFrEF (online only)

The Medical Letter on Drugs and Therapeutics • April 8, 2019; (Issue 1569)

...

View the Expanded Table: Some Drugs for HFrEF

Med Lett Drugs Ther. 2019 Apr 8;61(1569):e57-62 | Show Full Introduction Hide Full Introduction

Drugs for Hypertension

The Medical Letter on Drugs and Therapeutics • March 13, 2017; (Issue 1516)

in the US and their dosages, adverse effects, and costs are listed in the tables. Treatment of hypertensive urgencies and emergencies is not discussed...

in the US and their dosages, adverse effects, and costs are listed in the tables. Treatment of hypertensive urgencies and emergencies is not discussed here.

Med Lett Drugs Ther. 2017 Mar 13;59(1516):41-8 | Show Full Introduction Hide Full Introduction

Byvalson - A Beta Blocker/ARB Combination for Hypertension

The Medical Letter on Drugs and Therapeutics • September 12, 2016; (Issue 1503)

The FDA has approved Byvalson (Allergan), a fixed-dose combination of the beta blocker nebivolol (Bystolic) and the angiotensin receptor blocker (ARB) valsartan (Diovan, and generics), for treatment...

The FDA has approved Byvalson (Allergan), a fixed-dose combination of the beta blocker nebivolol (Bystolic) and the angiotensin receptor blocker (ARB) valsartan (Diovan, and generics), for treatment of hypertension. It is the only combination product that contains nebivolol, and the first to combine a beta blocker with an ARB.

Med Lett Drugs Ther. 2016 Sep 12;58(1503):115-7 | Show Full Introduction Hide Full Introduction

Sacubitril/Valsartan (Entresto) for Heart Failure

The Medical Letter on Drugs and Therapeutics • August 3, 2015; (Issue 1474)

The FDA has approved Entresto (Novartis), an oral fixed-dose combination of the neprilysin inhibitor sacubitril and the angiotensin receptor blocker (ARB) valsartan, to reduce the risk of cardiovascular...

The FDA has approved Entresto (Novartis), an oral fixed-dose combination of the neprilysin inhibitor sacubitril and the angiotensin receptor blocker (ARB) valsartan, to reduce the risk of cardiovascular death and heart failure hospitalization in patients with heart failure with reduced ejection fraction. Sacubitril is the first neprilysin inhibitor to become available in the US.

Med Lett Drugs Ther. 2015 Aug 3;57(1474):107-9 | Show Full Introduction Hide Full Introduction

Recombinant Human Parathyroid Hormone (Natpara)

The Medical Letter on Drugs and Therapeutics • June 8, 2015; (Issue 1470)

The FDA has approved a subcutaneously injected formulation of recombinant human parathyroid hormone (Natpara – NPS) as an adjunct to calcium and vitamin D to control hypocalcemia in adults with...

The FDA has approved a subcutaneously injected formulation of recombinant human parathyroid hormone (Natpara – NPS) as an adjunct to calcium and vitamin D to control hypocalcemia in adults with hypoparathyroidism. Natpara is an 84-amino acid single-chain polypeptide identical to native parathyroid hormone. It is the first parathyroid hormone formulation to be approved for this indication.

Med Lett Drugs Ther. 2015 Jun 8;57(1470):87-8 | Show Full Introduction Hide Full Introduction

Ivabradine (Corlanor) for Heart Failure

The Medical Letter on Drugs and Therapeutics • May 25, 2015; (Issue 1469)

The FDA has approved ivabradine (Corlanor – Amgen) to reduce the risk of hospitalization for worsening heart failure in adults with stable, symptomatic chronic heart failure with left ventricular ejection...

The FDA has approved ivabradine (Corlanor – Amgen) to reduce the risk of hospitalization for worsening heart failure in adults with stable, symptomatic chronic heart failure with left ventricular ejection fraction (LVEF) ≤35% who are in sinus rhythm with a resting heart rate ≥70 beats per minute and who are on maximum tolerated doses of beta blockers or have a contraindication to beta blocker use. Ivabradine has been available internationally for years as Procoralan and Corlentor for treatment of stable angina and heart failure.

Med Lett Drugs Ther. 2015 May 25;57(1469):75-6 | Show Full Introduction Hide Full Introduction

Glyxambi - A New Combination for Type 2 Diabetes

The Medical Letter on Drugs and Therapeutics • April 27, 2015; (Issue 1467)

The FDA has approved Glyxambi (Boehringer Ingelheim/Lilly), a fixed-dose combination of empagliflozin (Jardiance) and linagliptin (Tradjenta), for oral treatment of type 2 diabetes in adults. It is the...

The FDA has approved Glyxambi (Boehringer Ingelheim/Lilly), a fixed-dose combination of empagliflozin (Jardiance) and linagliptin (Tradjenta), for oral treatment of type 2 diabetes in adults. It is the first combination of a sodium-glucose co-transporter 2 (SGLT2) inhibitor and a dipeptidyl peptidase-4 (DPP-4) inhibitor to be approved in the US.

Med Lett Drugs Ther. 2015 Apr 27;57(1467):65-6 | Show Full Introduction Hide Full Introduction

Drugs for Chronic Heart Failure

The Medical Letter on Drugs and Therapeutics • January 19, 2015; (Issue 1460)

Heart failure is usually associated with left ventricular dysfunction. According to recent guidelines, patients with a left ventricular ejection fraction (LVEF) ≤40% are considered to have heart failure with reduced ejection fraction (HFrEF) or systolic heart failure. Patients with a LVEF ≥50% and symptoms of heart failure are considered to have heart failure with preserved ejection fraction (HFpEF) or diastolic heart failure; there is little evidence that drug treatment improves clinical outcomes in these patients. The treatment of acute heart failure is not included here.

Med Lett Drugs Ther. 2015 Jan 19;57(1460):9-13 | Show Full Introduction Hide Full Introduction

Drugs for Inflammatory Bowel Disease

The Medical Letter on Drugs and Therapeutics • August 4, 2014; (Issue 1448)

Aminosalicylates are effective for induction and maintenance of remission in mild to moderate ulcerative colitis. They are not recommended for treatment of Crohn's disease. FORMULATIONS — Oral mesalamine...

Aminosalicylates are effective for induction and maintenance of remission in mild to moderate ulcerative colitis. They are not recommended for treatment of Crohn's disease.

FORMULATIONS — Oral mesalamine is rapidly absorbed in the small intestine and most of the drug does not reach the colon. Pentasa releases mesalamine gradually throughout the gastrointestinal tract. Delzicol, Asacol HD, Lialda, and Apriso delay the release of the drug until it reaches the distal ileum and colon. Sulfasalazine (Azulfidine, and generics), balsalazide (Colazal, and others), and olsalazine (Dipentum) are prodrugs; mesalamine is azo-bonded to a second moiety and released in the colon following bacterial cleavage of the bond. Mesalamine is also available as an enema (Rowasa, and generics) and as a rectal suppository (Canasa).

Med Lett Drugs Ther. 2014 Aug 4;56(1448):65-72 | Show Full Introduction Hide Full Introduction

Drugs for Chronic Heart Failure

The Medical Letter on Drugs and Therapeutics • September 1, 2012; (Issue 121)

Chronic systolic heart failure is usually associated with a left ventricular ejection fraction (LVEF) of ≤40%. Many patients with symptoms of heart failure have higher ejection fractions, but there is no evidence that drug treatment of heart failure with preserved systolic function (LVEF >40%) improves clinical outcomes. Some of the drugs commonly used now for treatment of chronic heart failure are listed in the table on page 71.

Treat Guidel Med Lett. 2012 Sep;10(121):69-72 | Show Full Introduction Hide Full Introduction

Edarbyclor: An ARB/Chlorthalidone Combination for Hypertension

The Medical Letter on Drugs and Therapeutics • March 5, 2012; (Issue 1385)

The FDA has approved a fixed-dose combination of the angiotensin receptor blocker (ARB) azilsartan and the thiazide-like diuretic chlorthalidone as Edarbyclor (Takeda) for treatment of...

The FDA has approved a fixed-dose combination of the angiotensin receptor blocker (ARB) azilsartan and the thiazide-like diuretic chlorthalidone as Edarbyclor (Takeda) for treatment of hypertension

Med Lett Drugs Ther. 2012 Mar 5;54(1385):17-8 | Show Full Introduction Hide Full Introduction

Drugs for Hypertension

The Medical Letter on Drugs and Therapeutics • January 1, 2012; (Issue 113)

Drugs available in the US for treatment of chronic hypertension, with their dosages and adverse effects, are listed in the tables that begin on page 2. Combination products are listed on page 8. Drugs for treatment of hypertensive emergencies are not discussed here. They were reviewed previously.

Treat Guidel Med Lett. 2012 Jan;10(113):1-10 | Show Full Introduction Hide Full Introduction

Tribenzor for Hypertension

The Medical Letter on Drugs and Therapeutics • September 6, 2010; (Issue 1346)

Many patients with hypertension require more than one drug to control their blood pressure. Tribenzor (Daiichi Sankyo), recently approved by the FDA for treatment of hypertension, combines the calcium channel...

Many patients with hypertension require more than one drug to control their blood pressure. Tribenzor (Daiichi Sankyo), recently approved by the FDA for treatment of hypertension, combines the calcium channel blocker amlodipine (Norvasc, and others), the angiotensin receptor blocker (ARB) olmesartan (Benicar)and the most commonly prescribed diuretic, hydrochlorothiazide (HCTZ). Tribenzor is not approved for initial therapy, but is recommended for patients not adequately controlled on any 2-drug combination of a calcium channel blocker, an ARB or a diuretic.

Med Lett Drugs Ther. 2010 Sep 6;52(1346):70-1 | Show Full Introduction Hide Full Introduction

Intravenous Ibuprofen (Caldolor)

The Medical Letter on Drugs and Therapeutics • January 11, 2010; (Issue 1329)

An intraveneous (IV) formulation of ibuprofen (Caldolor - Cumberland) was recently approved by the FDA for use in adults. It can be administered alone for treatment of mild to moderate pain or as an adjunct to...

An intraveneous (IV) formulation of ibuprofen (Caldolor - Cumberland) was recently approved by the FDA for use in adults. It can be administered alone for treatment of mild to moderate pain or as an adjunct to opioid analgesics for moderate to severe pain. It is also approved for reduction of fever.

Med Lett Drugs Ther. 2010 Jan 11;52(1329):3-4 | Show Full Introduction Hide Full Introduction

Aliskiren/Valsartan (Valturna) for Hypertension

The Medical Letter on Drugs and Therapeutics • November 30, 2009; (Issue 1326)

The FDA has approved the use of aliskiren (Tekturna), a direct renin inhibitor, with valsartan (Diovan), an angiotensin-receptor blocker (ARB), in a fixed-dose combination as Valturna (Novartis) for treatment...

The FDA has approved the use of aliskiren (Tekturna), a direct renin inhibitor, with valsartan (Diovan), an angiotensin-receptor blocker (ARB), in a fixed-dose combination as Valturna (Novartis) for treatment of hypertension in patients already taking both drugs or not adequately controlled on monotherapy, and as initial therapy in those likely to need multiple drugs to control their blood pressure.

Med Lett Drugs Ther. 2009 Nov 30;51(1326):94-5 | Show Full Introduction Hide Full Introduction

Drugs for Treatment of Chronic Heart Failure

The Medical Letter on Drugs and Therapeutics • July 1, 2009; (Issue 83)

The range of drugs for treatment of chronic heart failure continues to expand. Some of those commonly used now are listed in the table on page 55. Mechanical therapies for the treatment of heart failure such as cardiac resynchronization, implanted cardiac defibrillators (ICDs), ventricular assist devices and ultrafiltration for the relief of congestion will not be reviewed here.

Treat Guidel Med Lett. 2009 Jul;7(83):53-6 | Show Full Introduction Hide Full Introduction

Exforge HCT

The Medical Letter on Drugs and Therapeutics • June 15, 2009; (Issue 1314)

Most patients with hypertension require more than one drug to control their blood pressure. Exforge HCT (Novartis) is a new 3-drug fixed-dose combination tablet approved by the FDA for treatment of...

Most patients with hypertension require more than one drug to control their blood pressure. Exforge HCT (Novartis) is a new 3-drug fixed-dose combination tablet approved by the FDA for treatment of hypertension. It combines the calcium-channel blocker amlodipine (Norvasc, and others) and the angiotensin receptor blocker (ARB) valsartan (Diovan), which are already available in a combination tablet (Exforge), with the most commonly prescribed diuretic hydrochlorothiazide (HCTZ). Exforge HCT is not approved for initial treatment of hypertension, but rather for patients not adequately controlled on a 2-drug combination of a calcium-channel blocker, an ARB or a diuretic. It can also be substituted for amlodipine, valsartan and HCTZ in patients already taking all 3 of these drugs.

Med Lett Drugs Ther. 2009 Jun 15;51(1314):46 | Show Full Introduction Hide Full Introduction

A Diuretic for Initial Treatment of Hypertension?

The Medical Letter on Drugs and Therapeutics • February 9, 2009; (Issue 1305)

Effective treatment of hypertension can prevent organ damage and death. The choice of drugs for initial treatment continues to be...

Effective treatment of hypertension can prevent organ damage and death. The choice of drugs for initial treatment continues to be controversial.

Med Lett Drugs Ther. 2009 Feb 9;51(1305):9-10 | Show Full Introduction Hide Full Introduction

Drugs for Hypertension

The Medical Letter on Drugs and Therapeutics • January 1, 2009; (Issue 77)

Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the tables that begin on page 2. Combination products are listed on page 9. Drugs for treatment of hypertensive emergencies are not discussed here. They were reviewed in Treatment Guidelines (volume 1, page 19, December 2002) and in The Medical Letter (volume 50, page 73, September 22, 2008).

Treat Guidel Med Lett. 2009 Jan;7(77):1-10 | Show Full Introduction Hide Full Introduction

Aliskiren/Hydrochlorothiazide (Tekturna HCT) for Hypertension

The Medical Letter on Drugs and Therapeutics • August 25, 2008; (Issue 1293)

Aliskiren (Tekturna - Novartis), the first direct renin inhibitor for treatment of hypertension, has been approved for use in a fixed-dose combination with the diuretic hydrochlorothiazide (Tekturna HCT -...

Aliskiren (Tekturna - Novartis), the first direct renin inhibitor for treatment of hypertension, has been approved for use in a fixed-dose combination with the diuretic hydrochlorothiazide (Tekturna HCT - Novartis). Many angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are also available in fixed-dose combinations with hydrochlorothiazide (HCTZ).

Med Lett Drugs Ther. 2008 Aug 25;50(1293):65-6 | Show Full Introduction Hide Full Introduction

Budesonide/Formoterol (Symbicort) for Asthma

The Medical Letter on Drugs and Therapeutics • February 11, 2008; (Issue 1279)

A combination of the corticosteroid budesonide and the long-acting beta2-agonist formoterol (Symbicort - AstraZeneca) has become available in a metered dose inhaler for long-term maintenance treatment of asthma...

A combination of the corticosteroid budesonide and the long-acting beta₂-agonist formoterol (Symbicort - AstraZeneca) has become available in a metered dose inhaler for long-term maintenance treatment of asthma in patients ≥ 12 years old. A combination product that contains fluticasone propionate and salmeterol (Advair) is already available for this indication in the US. Neither one of these combinations is approved for acute treatment of asthma symptoms. A dry powder inhaler formulation of Symbicort has been available in Europe and Canada for several years.

Med Lett Drugs Ther. 2008 Feb 11;50(1279):9-11 | Show Full Introduction Hide Full Introduction

Drugs for Treatment of Heart Failure

The Medical Letter on Drugs and Therapeutics • January 1, 2006; (Issue 41)

The choice of drugs for treatment of chronic heart failure continues to evolve. Those most commonly used now are listed in the table on page 3. The use of implanted cardiac defibrillators (ICDs) to reduce the incidence of sudden death in patients with heart failure and the treatment of decompensated heart failure were discussed in previous issues.

Treat Guidel Med Lett. 2006 Jan;4(41):1-4 | Show Full Introduction Hide Full Introduction

Drugs for Rheumatoid Arthritis

The Medical Letter on Drugs and Therapeutics • December 1, 2005; (Issue 40)

To prevent irreversible damage to joints and minimize toxicities associated with nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids, disease modifying anti-rheumatic drugs (DMARDs) are now used early in the treatment of rheumatoid arthritis (RA). The DMARDs listed in the table on page 84 have no immediate analgesic effects, but can control symptoms and have been shown to delay and possibly stop progression of the disease. The NSAIDs listed in the table on page 88 have analgesic and anti-inflammatory effects, but may not affect the disease process. Oral corticosteroids can rapidly relieve joint symptoms and control systemic manifestations, but their chronic use is associated with many complications.

Treat Guidel Med Lett. 2005 Dec;3(40):83-90 | Show Full Introduction Hide Full Introduction

BiDil for Heart Failure

The Medical Letter on Drugs and Therapeutics • September 28, 2005; (Issue 1218)

BiDil (NitroMed), a fixed-dose combination of isosorbide dinitrate and hydralazine, was approved by the FDA for adjunctive use in the treatment of heart failure in black patients.Both drugs are oral...

BiDil (NitroMed), a fixed-dose combination of isosorbide dinitrate and hydralazine, was approved by the FDA for adjunctive use in the treatment of heart failure in black patients.Both drugs are oral vasodilators that have been used together off-label for many years to treat heart failure in patients not responding to other drugs.

Med Lett Drugs Ther. 2005 Sep 28;47(1218):77-8 | Show Full Introduction Hide Full Introduction

Sildenafil (Revatio) for Pulmonary Arterial Hypertension

The Medical Letter on Drugs and Therapeutics • August 15, 2005; (Issue 1215)

The Medical Letter reported last year that sildenafil (Viagra - Pfizer) appeared to be effective for idiopathic pulmonary arterial hypertension (PAH), but confirmation from a controlled trial was needed. Now...

The Medical Letter reported last year that sildenafil (Viagra - Pfizer) appeared to be effective for idiopathic pulmonary arterial hypertension (PAH), but confirmation from a controlled trial was needed. Now the results of such a study are about to be published, and the drug has been approved by the FDA for this indication under the trade name Revatio.

Med Lett Drugs Ther. 2005 Aug 15;47(1215):65-7 | Show Full Introduction Hide Full Introduction

Drugs for Hypertension

The Medical Letter on Drugs and Therapeutics • June 1, 2005; (Issue 34)

Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the tables that begin on page 40. Combination products are listed on page 47. Drugs...

Treat Guidel Med Lett. 2005 Jun;3(34):39-48 | Show Full Introduction Hide Full Introduction

Performance-Enhancing Drugs

The Medical Letter on Drugs and Therapeutics • July 19, 2004; (Issue 1187)

With the 2004 Olympics only weeks away, performance-enhancing drugs will once again be receiving a great deal of attention. The US Anti-Doping Agency has published a list of drugs banned in Olympic sports (www.usantidoping.org) that includes, at least for some sports, all but 2 of the drugs reviewed here.

Med Lett Drugs Ther. 2004 Jul 19;46(1187):57-9 | Show Full Introduction Hide Full Introduction

Initial Therapy of Hypertension

The Medical Letter on Drugs and Therapeutics • July 5, 2004; (Issue 1186)

The importance of adequate control of hypertension in preventing organ damage and death is well established, but the choice of drugs is still controversial. Three recent drug trials, one supporting initial therapy with a diuretic, the second favoring an angiotensin converting enzyme (ACE) inhibitor, and the third showing equivalence between a calcium-channel blocker and an angiotensin-receptor blocker (ARB) have intensified the debate.

Med Lett Drugs Ther. 2004 Jul 5;46(1186):53-5 | Show Full Introduction Hide Full Introduction

Prevention and Treatment of Heat Injury

The Medical Letter on Drugs and Therapeutics • July 21, 2003; (Issue 1161)

Summer heat waves cause thousands of cases of heat-related illness in the US each year and hundreds of heat-related deaths, especially among the elderly. This review describes the contributing factors, clinical...

Med Lett Drugs Ther. 2003 Jul 21;45(1161):58-60 | Show Full Introduction Hide Full Introduction

Eplerenone (Inspra)

The Medical Letter on Drugs and Therapeutics • May 12, 2003; (Issue 1156)

Eplerenone (e pler' en one; Inspra - Pharmacia), an aldosterone receptor antagonist similar to spironolactone (Aldactone, and others), has been approved by the FDA, but not yet marketed, for treatment of...

Eplerenone (e pler' en one; Inspra - Pharmacia), an aldosterone receptor antagonist similar to spironolactone (Aldactone, and others), has been approved by the FDA, but not yet marketed, for treatment of hypertension. It has also been tried for treatment of heart failure.

Med Lett Drugs Ther. 2003 May 12;45(1156):39-40 | Show Full Introduction Hide Full Introduction

Drugs for Treatment of Heart Failure

The Medical Letter on Drugs and Therapeutics • April 1, 2003; (Issue 8)

The choice of drugs for treatment of chronic heart failure continues to evolve. It has become increasingly recognized that drugs used in heart failure produce beneficial effects through neurohormonal as well as hemodynamic mechanisms. The treatment of decompensated heart failure is not discussed here; drugs used for this indication were reviewed in Cardiovascular Drugs in the ICU, Treatment Guidelines from The Medical Letter 2002; 1:19.

Treat Guidel Med Lett. 2003 Apr;1(8):53-6 | Show Full Introduction Hide Full Introduction

Drugs for Hypertension

The Medical Letter on Drugs and Therapeutics • February 1, 2003; (Issue 6)

Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the table that begins on page 35. Combination products are listed on page 39. Drugs for treatment of hypertensive emergencies were discussed in Treatment Guidelines volume 1, issue 4, page 19, December 2002.

Treat Guidel Med Lett. 2003 Feb;1(6):33-40 | Show Full Introduction Hide Full Introduction

Drugs for Rheumatoid Arthritis

The Medical Letter on Drugs and Therapeutics • January 1, 2003; (Issue 5)

Many different drugs are now used to treat rheumatoid arthritis. Nonsteroidal anti-inflammatory drugs (NSAIDs), listed in the table on page 26, have analgesic and anti-inflammatory effects, but may not affect the disease process. Corticosteroids can provide rapid relief of joint symptoms and control of systemic manifestations, but chronic use is associated with many complications. The "disease-modifying" anti-rheumatic drugs (DMARDs), listed on page 29, have no immediate analgesic effects, but can control symptoms and may delay progression of the disease (American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines, Arthritis Rheum 2002; 46:328). Interactions of anti-rheumatic drugs with other drugs are listed in The Medical Letter Handbook of Adverse Drug Interactions, 2003.

Treat Guidel Med Lett. 2003 Jan;1(5):25-32 | Show Full Introduction Hide Full Introduction

Drugs for Hypertension

The Medical Letter on Drugs and Therapeutics • March 5, 2001; (Issue 1099)

Drugs available in the USA for treatment of chronic hypertension, their dosages and adverse affects are listed in the table and discussed in the...

Drugs available in the USA for treatment of chronic hypertension, their dosages and adverse affects are listed in the table and discussed in the text.

Med Lett Drugs Ther. 2001 Mar 5;43(1099):17-22 | Show Full Introduction Hide Full Introduction

Beta-blockers For Heart Failure

The Medical Letter on Drugs and Therapeutics • June 26, 2000; (Issue 1081)

Standard treatment for patients with heart failure has included a diuretic, digitalis and an ACE inhibitor. In recent years carvedilol, a nonselective beta-blocker with alpha-1 blocking activity, and the beta-selective blockers bisoprolol and metroprolol have also been used for this indication.

Med Lett Drugs Ther. 2000 Jun 26;42(1081):54-5 | Show Full Introduction Hide Full Introduction

Drugs for Hypertension

The Medical Letter on Drugs and Therapeutics • March 12, 1999; (Issue 1048)

Drugs available in the USA for treatment of chronic hypertension, their dosages and adverse affects are listed in the table and discussed in the...

Drugs available in the USA for treatment of chronic hypertension, their dosages and adverse affects are listed in the table and discussed in the text.

Med Lett Drugs Ther. 1999 Mar 12;41(1048):23-8 | Show Full Introduction Hide Full Introduction

Drugs for Chronic Heart Failure

The Medical Letter on Drugs and Therapeutics • January 29, 1999; (Issue 1045)

...

The choice of drugs for treatment of heart failure depends on both hemodynamic and neurohormonal factors.

Med Lett Drugs Ther. 1999 Jan 29;41(1045):12-4 | Show Full Introduction Hide Full Introduction

Fenoldopam--A New Drug for Parenteral Treatment of Severe Hypertension

The Medical Letter on Drugs and Therapeutics • May 22, 1998; (Issue 1027)

Fenoldopam mesylte (Corlopam - Neurex), a peripheral dopamine-1 (DA1) agonist, has been approved by the FDA for parenteral use in lowering blood pressure. The manufacturer claims that, unlike other parenteral...

Fenoldopam mesylte (Corlopam - Neurex), a peripheral dopamine-1 (DA₁) agonist, has been approved by the FDA for parenteral use in lowering blood pressure. The manufacturer claims that, unlike other parenteral antihypertensive agents, fenoldopam not only lowers blood pressure but also maintains or improves renal function.

Med Lett Drugs Ther. 1998 May 22;40(1027):57-8 | Show Full Introduction Hide Full Introduction

Carvedilol for Heart Failure

The Medical Letter on Drugs and Therapeutics • September 26, 1997; (Issue 1010)

Carvedilol (Coreg - SmithKline Beecham and Boehringer-Mannheim), a betaadrenergic and alpha-adrenergic blocker approved by the FDA for treatment of hypertension in 1995, but not marketed at that time, has now...

Carvedilol (Coreg - SmithKline Beecham and Boehringer-Mannheim), a betaadrenergic and alpha-adrenergic blocker approved by the FDA for treatment of hypertension in 1995, but not marketed at that time, has now been approved and marketed for treatment of mild or moderate (NYHA class II or III) heart failure stabilized on other drugs. It is being promoted as an add-on drug that reduces the morbidity and mortality of the disease.

Med Lett Drugs Ther. 1997 Sep 26;39(1010):89-91 | Show Full Introduction Hide Full Introduction

Drugs for Chronic Heart Failure

The Medical Letter on Drugs and Therapeutics • October 11, 1996; (Issue 985)

Cardiologist now emphasize the importance of neurohormonal as well as hemodynamic factors in the pathophysiology of chronic heart failure (JN Cohn, N Engl J Med, 335:490, August 15, 1996). Drugs that act on...

Med Lett Drugs Ther. 1996 Oct 11;38(985):92-4 | Show Full Introduction Hide Full Introduction

Torsemide (Demadex) - A New Loop Diuretic

The Medical Letter on Drugs and Therapeutics • August 19, 1994; (Issue 929)

Torsemide, a new loop diuretic similar in action to bumetanide (Bumex) and furosemide, was recently approved by the US Food and Drug Administration for treatment of edema due to congestive heart failure, renal...

Torsemide, a new loop diuretic similar in action to bumetanide (Bumex) and furosemide, was recently approved by the US Food and Drug Administration for treatment of edema due to congestive heart failure, renal disease, or hepatic disease and also for treatment of hypertension. It is available for both oral and intravenous use.

Med Lett Drugs Ther. 1994 Aug 19;36(929):73-4 | Show Full Introduction Hide Full Introduction

Drugs for Chronic Heart Failure

The Medical Letter on Drugs and Therapeutics • May 14, 1993; (Issue 896)

Chronic heart failure results from an iterplay between hemodynamic and neurohormonal factors (M Packer, Lancet, 340:88, 92, 1992). For patients with heart failure due to left ventricular dysfunction, drugs that decrease cardicac preload and afterload and those that increase contractility are commonly used together.

Med Lett Drugs Ther. 1993 May 14;35(896):40-2 | Show Full Introduction Hide Full Introduction

Flosequinan for Heart Failure

The Medical Letter on Drugs and Therapeutics • March 19, 1993; (Issue 892)

Flosequinan (Manoplax - Boots), a fluoroquinolone derivative, is now available in the USA for treatment of congestive heart failure. Labeling approved by the US Food and Drug Administration recommends the...

Flosequinan (Manoplax - Boots), a fluoroquinolone derivative, is now available in the USA for treatment of congestive heart failure. Labeling approved by the US Food and Drug Administration recommends the drug only for patients who cannot tolerate or have not responded adequately to an angiotensin-converting enzyme (ACE) inhibitor.

Med Lett Drugs Ther. 1993 Mar 19;35(892):23-4 | Show Full Introduction Hide Full Introduction

Isradipine For Hypertension

The Medical Letter on Drugs and Therapeutics • May 31, 1991; (Issue 845)

Isradipine (DynaCirc - Sandoz), a dihydropyridine calcium-channel blocker chemically related to nicardipine (Cardene) and nifedipine (Procardia, and others), was recently approved by the US Food and Drug...

Isradipine (DynaCirc - Sandoz), a dihydropyridine calcium-channel blocker chemically related to nicardipine (Cardene) and nifedipine (Procardia, and others), was recently approved by the US Food and Drug Administration for oral treatment of hypertension.

Med Lett Drugs Ther. 1991 May 31;33(845):51-2 | Show Full Introduction Hide Full Introduction

Doxazosin For Treatment of Hypertension

The Medical Letter on Drugs and Therapeutics • February 22, 1991; (Issue 838)

Doxazosin (mesylate - Roerig), an alpha1-adrenergic receptor blocker similar to prazosin (Minipress, and others) and terazosin (Hytrin), was recently approved by the US Food and Drug Administration for...

Doxazosin (mesylate - Roerig), an alpha1-adrenergic receptor blocker similar to prazosin (Minipress, and others) and terazosin (Hytrin), was recently approved by the US Food and Drug Administration for treatment of hypertension.

Med Lett Drugs Ther. 1991 Feb 22;33(838):15-6 | Show Full Introduction Hide Full Introduction

Moricizine for Cardiac Arrhythmias

The Medical Letter on Drugs and Therapeutics • November 2, 1990; (Issue 830)

Moricizine (mor i'; siz een) hydrochloride (Ethmozine - Du Pont), a class I antiarrhythmic drug developed in the USSR, was recently approved by the US Food and Drug Administration (FDA) for oral treatment of...

Moricizine (mor i'; siz een) hydrochloride (Ethmozine - Du Pont), a class I antiarrhythmic drug developed in the USSR, was recently approved by the US Food and Drug Administration (FDA) for oral treatment of life-threatening ventricular arrhythmias.

Med Lett Drugs Ther. 1990 Nov 2;32(830):99-100 | Show Full Introduction Hide Full Introduction

Treatment of Heat Injury

The Medical Letter on Drugs and Therapeutics • July 13, 1990; (Issue 822)

Summer heat waves cause thousands of cases of heat-related illness in the USA each year and hundreds of heat-related deaths, especially among the elderly. A few principles may be helpful in preventing and...

Med Lett Drugs Ther. 1990 Jul 13;32(822):66-8 | Show Full Introduction Hide Full Introduction

Is Indapamide (Lozol) Safer Than A Thiazide?

The Medical Letter on Drugs and Therapeutics • November 17, 1989; (Issue 805)

Recent advertisements for indapamide (Lozol - Rorer), an oral antihypertensive/diuretic (Medical Letter, 26:17, 1984), claim that the drug, unlike thiazide diuretics, does not significantly increase serum...

Recent advertisements for indapamide (Lozol - Rorer), an oral antihypertensive/diuretic (Medical Letter, 26:17, 1984), claim that the drug, unlike thiazide diuretics, does not significantly increase serum cholesterol and has a minimal impact on potassium. Indapamide has no thiazide ring but, like chlorthalidone (Hygroton; and others) and hydrochlorothiazide (HydroDiuril; and others), it does have a sulfamoyl benzamide moiety, which is probably responsible for its natriuretic and diuretic effects. Unlike the thiazides, it also has a methylindoline moiety, which apparently decreases peripheral resistance.

Med Lett Drugs Ther. 1989 Nov 17;31(805):103 | Show Full Introduction Hide Full Introduction

Carteolol and Penbutolol For Hypertension

The Medical Letter on Drugs and Therapeutics • July 28, 1989; (Issue 797)

Carteolol (Cartrol - Abbott) and penbutolol (Levatol - Reed & Carnrick), two oral beta-adrenergic blocking drugs, were recently approved by the US Food and Drug Administration for once-daily treatment of...

Carteolol (Cartrol - Abbott) and penbutolol (Levatol - Reed & Carnrick), two oral beta-adrenergic blocking drugs, were recently approved by the US Food and Drug Administration for once-daily treatment of systemic hypertension. Both drugs are non-selective beta-blockers with mild partial agonist activity. Beta-blockers currently available in the USA for treatment of hypertension are listed in the table on the next page.

Med Lett Drugs Ther. 1989 Jul 28;31(797):70-1 | Show Full Introduction Hide Full Introduction

Diclofenac

The Medical Letter on Drugs and Therapeutics • December 2, 1988; (Issue 780)

Diclofenac sodium (Voltaren - Geigy), a nonsteroidal anti-inflammatory drug (NSAID) available in some countries since 1974, was recently introduced in the USA for treatment of rheumatoid arthritis,...

Diclofenac sodium (Voltaren - Geigy), a nonsteroidal anti-inflammatory drug (NSAID) available in some countries since 1974, was recently introduced in the USA for treatment of rheumatoid arthritis, osteoarthritis and ankylosing spondylitis. It is being promoted as 'The number one prescribed antiarthritic in the world.'

Med Lett Drugs Ther. 1988 Dec 2;30(780):109-11 | Show Full Introduction Hide Full Introduction

ACE Inhibitors for Congestive Heart Failure

The Medical Letter on Drugs and Therapeutics • October 21, 1988; (Issue 777)

The angiotensin-converting enzyme (ACE) inhibitors captopril (Capoten - Squibb) and enalapril (Vasotec - Merck) are now widely used to treat chronic congestive heart failure that has not responded adequately...

The angiotensin-converting enzyme (ACE) inhibitors captopril (Capoten - Squibb) and enalapril (Vasotec - Merck) are now widely used to treat chronic congestive heart failure that has not responded adequately to digitalis and diuretics (Medical Letter, 30:13, Jan 29, 1988). Recently, some cardiologists have debated whether ACE inhibitors should also be used as first-line agents for treatment of this condition (WW Parmley et al, J Am Coll Cardiol, 12:265, July 1988).

Med Lett Drugs Ther. 1988 Oct 21;30(777):97-8 | Show Full Introduction Hide Full Introduction

Treatment of Xerostomia

The Medical Letter on Drugs and Therapeutics • July 29, 1988; (Issue 771)

Xerostomia, dry mouth due to decreased or absent saliva, is a common problem, particularly among elderly patients. Decreased salivary flow can be due to many different conditions, including drug therapy, Sj...

Med Lett Drugs Ther. 1988 Jul 29;30(771):74-6 | Show Full Introduction Hide Full Introduction

Microx

The Medical Letter on Drugs and Therapeutics • June 17, 1988; (Issue 768)

Microx (Pennwalt), a new low-dosage formulation of the thiazide-type diuretic metolazone (Zaroxolyn; Diulo), was recently marketed in the USA. The manufacturer claims that the low dose of controls...

Microx (Pennwalt), a new low-dosage formulation of the thiazide-type diuretic metolazone (Zaroxolyn; Diulo), was recently marketed in the USA. The manufacturer claims that the low dose of controls hypertension with less potassium loss, making it safer than other diuretics and as effective as combination drugs, such as Dyazide, that include both a thiazide and a potassium-sparing diuretic. Medical Letter consultants generally do not recommend Dyazide or other fixed-dose combinations for treatment of hypertension.

Med Lett Drugs Ther. 1988 Jun 17;30(768):63-4 | Show Full Introduction Hide Full Introduction

Lisinopril For Hypertension

The Medical Letter on Drugs and Therapeutics • April 8, 1988; (Issue 763)

- Merck; Zestril - Stuart), a new angiotensin-converting enzyme (ACE) inhibitor, was recently approved by the US Food and Drug Administration (FDA) for once-daily treatment of . Two other ACE inhibitors,...

- Merck; Zestril - Stuart), a new angiotensin-converting enzyme (ACE) inhibitor, was recently approved by the US Food and Drug Administration (FDA) for once-daily treatment of . Two other ACE inhibitors, captopril (Capoten - Squibb) and e

Med Lett Drugs Ther. 1988 Apr 8;30(763):41-2 | Show Full Introduction Hide Full Introduction

Vasodilators For Congestive Heart Failure

The Medical Letter on Drugs and Therapeutics • January 29, 1988; (Issue 758)

Vasodilators are widely used for treatment of congestive heart failure (CHF) that has not responded adequately to diuretics and digitalis. Vasodilator drugs redistribute blood volume in patients with heart failure, lowering pressure and reducing volume in the failing left ventricle, which leads to increased cardiac output, decreased pulmonary capillary wedge pressure, and improved exercise tolerance. Since the last Medical Letter review of this subject (Volume 26, page 115, 1984), some additional data have become available.

Med Lett Drugs Ther. 1988 Jan 29;30(758):13-4 | Show Full Introduction Hide Full Introduction